Genetic Technologies Limited · ASX:GTG
Genetic Technologies — HC Wainwright 22nd Annual Global Investment Conference 2020
19 slides from Genetic Technologies's conference presentation, Sep 16, 2020
Slide 1: ASX Market Announcement
ASX Market Announcement Investor Presentation For personal use only MELBOURNE, AUSTRALIA, September 16, 2020 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, is pleased to announce that the Company is presenting at t
Slide 2: About Genetic Technologies Limited
About Genetic Technologies Limited For personal use only Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products G
Slide 3: HC Wainwright 22nd Annual Global Investment Conference
For personal use only NASDAQ: GENE HC Wainwright & Co 22nd Annual Global Investment Conference 14-16 September 2020
Slide 4: Forward looking statements
Forward looking statements For personal use only This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business ach
Slide 5: Genetic Technologies is a leader in genomics
Genetic Technologies is a leader in genomics For personal use only q Over a decade of R&D surrounding the development of polygenic risk scores Company Snapshot: with an extensive Patent Portfolio q Creator of Laboratory Developed Tests (LDT) supported by proprietary - Market capitalization as at 10
Slide 6: Polygenic (Genetic) Risk Score
Polygenic (Genetic) Risk Score For personal use only Our Platform • Most common complex diseases (CCD) are a result of many genes acting in concert • Polygenic Risk Score is a DNA based risk assessment (screening) tool that weighs a person’s odds of developing a CCD by inspecting the genome (DNA) •
Slide 7: Polygenic Risk Scores (PRS) Platform
Polygenic Risk Scores (PRS) Platform Proprietary platform developed over the past decade and supports multiple PRS tests targeting For personal use only healthy individuals to identify serious disease risk. • PRS is a DNA based risk assessment tool that weighs a person’s odds of developing common co
Slide 8: Product test pipeline and status
Product test pipeline and status • Our platform supports risk predictive testing in major oncological, metabolic, regenerative and infectious disease indications For personal use only (including COVID-19) • Our tests in market and development cover up to 70% off causes of morbidity and mortality in
Slide 9: Disease coverage
Disease coverage For personal use only • Our product development strategy aims to provide coverage of the most significant causes of morbidity and mortality in the US • It covers up to 70% of causes of mortality Incidence of underlying causes of mortality in the US Breast Cancer Colorectal Cancer Ty
Slide 10: World-first polygenic risk test for breast cancer
GTG has developed a world-first polygenic risk test for breast cancer For personal use only Easy-to-use test solves Risk stratification enables precision screening and personalised prevention the compliance problem Simple cheek swab that help determine a Breast Cancer Risk Assessment Final Test Repo
Slide 11: World-first polygenic risk test for colorectal cancer
GTG has developed a world-first polygenic risk test for colorectal cancer For personal use only Easy-to-use test solves the compliance problem Risk stratification enables precision screening and personalised prevention Clinically actionable results 5-year, 10-year and lifetime risk Informs screening
Slide 12: COVID-19 sdr (serious disease risk)
For personal use only COVID-19 sdr (serious disease risk) 10
Slide 13: COVID-19 at a glance
COVID-19 at a glance For personal use only • About 30 million confirmed COVID-19 cases worldwide, with a mortality of almost 1 million* • Pandemic management strategies vary depending on country, but mostly one size fits all approaches • New Normal = maintaining social restrictions (distancing/isola
Slide 14: COVID-19 sdr (serious disease risk)
COVID-19 sdr (serious disease risk) For personal use only • COVID-19 sdr is Genetic Technology’s COVID-19 Response – a low-cost, accurate assessment tool that is designed to assist in pandemic management in lieu of a vaccine • It is the world’s first genomic test to predict the risk of hospitalizati
Slide 15: Development Progress To-Date
Development Progress To-Date For personal use only COVID-19 sdr is The Test is in Beta designed to enable • The first clinical kit due in Q3 2020 the targeting of limited vaccine resources to those Fast-tracking development at highest risk of • In discussions with major international reagent supplie
Slide 16: Suggested use of Genetype's COVID-19 Serious Disease Risk
For personal use only Suggested use of Genetype’s COVID-19 Serious Disease Risk - Simple to implement - Suitable for people aged 30-65 - Designed to identify high risk and low risk individuals - Can be offered as a priority to first responders, health workers, transport and food supply groups - Coul
Slide 17: Intellectual property is a core advantage
Intellectual property is a core advantage For personal use only GTG has a strong patent portfolio covering the breast cancer risk assessment test 5 Patents granted in the US 7 Patent families pending • Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of the core genetic markers included
Slide 18: The Next months
The Next 12 months: For personal use only + Complete development of High density multi disease tests covering >70% mortality in western society using a single swab and delivering low cost, accurate risk data. + Establish new divisions: Oncology, Metabolic diseases, Cardiovascular disease, Mental hea
Slide 19: Our board
Our board For personal use only Dr. Jerzy “George” Muchnicki Dr. Lindsay Wakefield MBBS MBBS Executive Director & Chief Executive Officer (Interim) Non – Executive Director Mr. Peter Rubinstein Mr Nick Burrows B.Com, FAICD, FCA, FGIA, FTIA, F Fin BSc, BEc, LLB Non – Executive Director Chairman - Non
Genetic Technologies — HC Wainwright 22nd Annual Global Investment Conference 2020 on 6ix